randomisation (Cenduit GmbH)
90
Structured Review
Cenduit GmbH
randomisation
Randomisation, supplied by Cenduit GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/randomisations/randomisation+list/pmc04532697-161-0-4
Average 90 stars, based on 1 article reviews
Randomisation, supplied by Cenduit GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/randomisations/randomisation+list/pmc04532697-161-0-4
Average 90 stars, based on 1 article reviews
randomisation - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial Article Snippet: The Article Title: Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study Article Snippet: All randomisation procedures were managed by a Article Title: Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study Article Snippet: The randomization list and study medication blind were provided and maintained by a web-based randomization system provided by an independent Article Title: Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial Article Snippet: The computer-generated randomization schedule was provided to the Article Title: Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder. Article Snippet: Department of Urology, En Chu Kong Hospital, College of Medicine, National Taiwan University, New Taipei City, Taiwan Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan, Taiwan Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, and Buddhist Tzu Chi University, Hualien, Taiwan Department of Statistics, National Taipei University, New Taipei City, Taiwan Sequencing:Article Title: Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial Article Snippet: Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China (Prof Y-L Wu MD, Prof J-J Yang MD); Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy (Prof V Guarneri PhD); Hospital Umum Sarawak, Kuching, Sarawak, Malaysia (P J Voon MD); Department of Internal and Respiratory Medicine, Sunway Medical Centre, Selangor, Malaysia (B K Lim MRCP); Service de Pneumologie, Hôpital Cochin, Assistance Publique—Hôpitaux de Paris, Paris, France (Prof M Wislez PhD); Université Paris Cité, Paris, France (Prof M Wislez); Department of Thoracic Oncology, Fujian Cancer Hospital, Fuzhou, China (Prof C Huang PhD); Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia (Prof C K Liam MBBS [UM]); CHU de Toulouse, Université Paul Sabatier, Toulouse, France (Prof J Mazieres PhD); Department of Oncology, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia (L M Tho PhD); Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan (Prof H Hayashi PhD); National Lung Hospital, University of Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial Article Title: Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial. Article Snippet: Published Online xxx https://doi.org/10.. 1016/j.ebiom.2023.. 104923 Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial Nicholas C. Cullen, Petr Novak,b,∗ Duygu Tosun, Branislav Kovacech, Jozef Hanes, Eva Kontsekova, Michal Fresser, Stefan Ropele, Howard H. Feldman, Reinhold Schmidt, Bengt Winblad, and Norbert Zilka Generated:Article Title: Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial Article Snippet: Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China (Prof Y-L Wu MD, Prof J-J Yang MD); Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy (Prof V Guarneri PhD); Hospital Umum Sarawak, Kuching, Sarawak, Malaysia (P J Voon MD); Department of Internal and Respiratory Medicine, Sunway Medical Centre, Selangor, Malaysia (B K Lim MRCP); Service de Pneumologie, Hôpital Cochin, Assistance Publique—Hôpitaux de Paris, Paris, France (Prof M Wislez PhD); Université Paris Cité, Paris, France (Prof M Wislez); Department of Thoracic Oncology, Fujian Cancer Hospital, Fuzhou, China (Prof C Huang PhD); Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia (Prof C K Liam MBBS [UM]); CHU de Toulouse, Université Paul Sabatier, Toulouse, France (Prof J Mazieres PhD); Department of Oncology, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia (L M Tho PhD); Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan (Prof H Hayashi PhD); National Lung Hospital, University of Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial Article Title: Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial. Article Snippet: Published Online xxx https://doi.org/10.. 1016/j.ebiom.2023.. 104923 Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial Nicholas C. Cullen, Petr Novak,b,∗ Duygu Tosun, Branislav Kovacech, Jozef Hanes, Eva Kontsekova, Michal Fresser, Stefan Ropele, Howard H. Feldman, Reinhold Schmidt, Bengt Winblad, and Norbert Zilka Produced:Article Title: Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial Article Snippet: .. Cenduit produced the |
